Sanofi has revealed solid but underwhelming topline Phase II results from its delayed COVID-19 vaccine, which showed the neutralizing antibody levels produced were ‘comparable’ to that produced by a natural infection.
The company has not yet published the full data either in a pre-print publication or academic journal, but the results...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

